Sewoonmedical Co., Ltd.

Sewoonmedical Co., Ltd.

KKRX:100700
2,320.00
KRW
-5.00
(-0.22%)
305.53EPS
8.51P/E
106.50BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,189.2
1,217.72
1,294.44
1,308.93
1,414.48
1,455.26
1,545.41
1,475.5
1,447.08
1,386.44
1,574.2
1,389.71
1,490.93
1,517.32
Basic EPS, GAAP
197
138
71
193
212
223
219
243
284
240
345
281
279
296.78
Free Cash Flow per Basic Share
156.04
10.68
-12.87
-35.16
72.03
154.62
173.81
364.98
438.88
163.99
487.17
266.48
376.47
368.31
Dividend per Share
16.02
19.94
25.08
25.02
42.97
39.92
50.03
50.12
50.05
49.92
59.91
70.01
60.84
- -
Book Value per Share
1,335.88
1,463
1,515.65
1,688.4
1,795.22
1,994.6
2,199.45
2,355.58
2,636.45
2,841.35
3,122.05
3,375.24
3,584.23
3,624.11
Tangible Book Value per Share
1,266.55
1,395.46
1,454.68
1,647.09
1,761.13
1,967.62
2,179.68
2,319.35
2,599.55
2,813.26
3,100.28
3,345.99
3,562.28
3,603.54
Basic Weighted Avg Shares
43
43
43
43
43
43
43
43
43
43
43
43
43
43
Sales/Revenue/Turnover
51,423
52,871
55,867
56,620
61,230
63,121
66,869
63,729
62,579
60,116
68,247
60,151
63,657
64,489
Operating Margin (%)
21.53
19.58
16.92
20.73
20.37
28.45
25.29
22.59
24.61
20.27
24.79
18.91
19.95
20.67
Depreciation Expense
2,331
2,322
2,513
2,551
3,006
3,118
3,497
3,684
3,836
3,888
3,648
3,480
3,320
3,259
Net Income, GAAP
8,519
5,992
3,064
8,349
9,177
9,672
9,476
10,496
12,282
10,406
14,957
12,163
11,912
12,614
Effective Tax Rate (%)
18.62
18.21
26.15
22.34
26.98
22.88
15.99
20.86
23.24
21.94
19.82
19.5
18.18
19
Profit Margin (%)
16.57
11.33
5.49
14.74
14.99
15.32
14.17
16.47
19.63
17.31
21.92
20.22
18.71
19.56
Working Capital
33,135
34,809
32,638
35,250
39,919
48,256
53,606
62,567
74,659
84,891
99,632
112,371
120,296
121,524
LT Debt
70
- -
- -
- -
- -
- -
613
701
644
758
622
772
612
680
Total Equity
58,722
64,349
66,647
74,268
78,676
87,710
96,177
103,281
115,921
125,024
137,693
149,066
154,401
156,242
Return on Invested Capital (%)
16.11
13.51
10.59
12.4
11.25
16
14.93
11.19
10.51
7.72
10.13
6.28
6.75
6.98
Return on Capital (%)
15.13
9.51
4.65
11.36
11.57
11
9.66
10.12
10.7
8.4
10.94
8.16
7.64
7.99
Return on Common Equity (%)
15.76
9.89
4.75
12.04
12.17
11.79
10.44
10.65
11.37
8.78
11.59
8.65
8.01
8.44

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
211
152
136
LT Borrowings
- -
- -
- -
LT Finance Leases
598
612
680
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
42
Market Capitalization
105,864
102,701
106,497

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
123,926
129,155
131,943
Cash, Cash Equivalents & STI
92,148
97,024
99,845
Accounts Receivable, Net
13,312
13,088
12,818
Inventories
16,944
16,976
16,926
Total Current Liabilities
8,085
8,858
10,418
Payables & Accruals
- -
- -
- -
ST Debt
211
152
136
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.79%
8.41%
3.58%
Free Cash Flow
25.46%
29.77%
39.36%
Net Income, GAAP
22.12%
4.95%
-2.06%
Sales/Revenue/Turnover
1.56%
0.35%
5.83%
Total Cash Common Dividend
- -
- -
-14.29%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14,839
15,282
14,971
15,058
60,151
2025
14,562
15,673
16,834
16,588
63,657
2026
15,394
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
87
68
54
72.53
281
2025
63
44.87
87.26
84
279
2026
81.37
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
70.01
2025
- -
- -
- -
- -
60.84
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jae-Hee Lee
Full Time Employees
187
Sector
Health technology
Industry
Medical specialties
Address
Cheonan South Korea
IPO Date
Sep 30, 2008
Business
Sewoonmedical Co., Ltd. is a South Korea-based medical device manufacturer primarily engaged in the development, manufacturing, and distribution of disposable medical consumables, surgical equipment, and specialized therapeutic apparatus for clinical healthcare providers and medical institutions. Founded in 1969 and incorporated in 1982, the company is headquartered in Cheonan-si, Chungcheongnam-do, South Korea, and is publicly traded on the Korean Exchange under the ticker 100700. The company operates across multiple specialized healthcare segments, offering a comprehensive product portfolio that comprises wound drainage systems, including closed-wound suction units under the BAROVAC brand, surgical drainage bottles, and suction tubing; urological and drainage catheters, including silicone and latex Foley balloon catheters, nephrostomy catheters, ureteral catheters, and external ventricular drainage systems; respiratory and anesthesia devices, including endotracheal tubes, tracheostomy tubes, suction catheters, and airway management consumables; specialized electrosurgical and therapeutic equipment, including blood and intravenous fluid warmers marketed under the ThermoSens brand, non-vascular and gastrointestinal stents under the BONASTENT line, and nerve localization devices under the EpiStim brand; and general infusion and surgical supplies, including intravenous infusion sets, 3-way stopcocks, extension lines, syringe components, and medical gloves. Sewoonmedical operates domestic manufacturing facilities in South Korea and maintains an overseas production subsidiary, Sewoon Medical Vina Co., Ltd., in Vietnam to optimize cost efficiency and scale manufacturing output. The company holds international regulatory clearances and quality certifications, including ISO 13485, CE marking, and U.S. FDA approvals, serving domestic hospitals and exporting products to international markets across Asia, Europe, North America, and the Middle East. In recent developments, Sewoonmedical has expanded production output and operational capacity at its Vietnam manufacturing facility to address rising global demand and ensure supply chain resilience for essential medical consumables. The company has also prioritized the expansion of its high-margin medical equipment portfolio through upgraded iterations of its ThermoSens fluid warming devices and specialized surgical drainage products, alongside targeted research and development into advanced biocompatible coatings and infection-prevention catheter technologies to meet evolving international medical device regulatory standards.